Kenny Ausubel spent 20 years of the prime of his life researching a story that everyone needs to know. Paragraph by paragraph, he reveals the motivations of those who would deprive suffering patients of history's most successful cancer treatment.
Personally, I have never been able to take Hoxsey the man seriously, but what erudition Hoxsey lacked, Dr. Frederic Mohs had in abundance -- and what is extraordinary is that their bloodroot paste formulae were essentially identical. Hoxsey was persecuted for his efforts to make his treatment available; the Mohs microsurgery method is now widely accepted and practiced in such illustrious institutions as Harvard Medical School.
Ergo, the pattern of suppression detailed in Ausubel's book is all the more important because it was not based on science but rather on the politics of medicine, something that demands questioning since fifty years later, the basic problem is not solved.
There is no question but that the public deserves access to anything that might alleviate suffering, prolong lives, or cure them of their illnesses. The Government is charged with protecting the public from fraud; but in its zeal to brand outsiders as quacks, it has lost focus on the humanitarian as well as clinical aspects of healing.
I therefore disagree vehemently with the review posted below by fraud investigator. Hoxsey made his money in oil and operated affordable facilities for people seeking a cure for cancer. Yes, he was lacking proper credentials, but knowledge and experience can be acquired in clinical settings where keenly observant people can by-pass indoctrination and determine whether or not patients are responding well to treatment. This point is important because in the greed for patents, the factors that determine patentability are seldom well aligned with the factors that determine efficacy and safety.
The Pacific Yew/taxol issue is a case in point. In its whole form, there are cytotoxic agents and those that protect the patient from harmful side effects. However, to patent a product, one must choose one or the other of the active principles of the herb. The end result is a product that poses significant risk factors to the patient.
In 1000 words or less, one cannot end the debate. My point is simply that the formal approval process is a patenting process, not a test of what is in the long-term best interests of the patient. If investors are to develop a drug that is unique enough to be patented and destructive enough to be approved, laboratories must ignore the whole in an effort to maximize the economic rewards of the part.
In my opinion, this system has gone too far. At this point, it serves industry rather than humanity. Kenny Ausubel has presented a detailed and insightful and extremely well documented case of persecution of a person and a method that constitutes a crime against the very patients who might benefit from a treatment that often succeeds where others fail. Read the book and make up your own mind.